Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
在强直性脊柱炎患者中，CT-P13 与参考药物英夫利昔单抗的长期疗效相当，这通过患者报告结局、安全性和药代动力学评估得出：来自随机、平行组 PLANETAS 研究的 54 周结果
期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-016-0930-4
Park, Won; Yoo, Dae Hyun; Jaworski, Janusz; Brzezicki, Jan; Gnylorybov, Andriy; Kadinov, Vladimir; Sariego, Irmgadt Goecke; Abud-Mendoza, Carlos; Escalante, William Jose Otero; Kang, Seong Wook; Andersone, Daina; Blanco, Francisco; Hong, Seung Suh; Lee, Sun Hee; Braun, Jürgen
